This impaired anti-tumor ability might be attributable to the decreased accumulation of iNKT cells in the lungs and damage to their production of critical anti-tumor factors (IFN-γ and CCL5) after α-GalCer administration (days 0 and 4) (Fig. 7d–g and Supplementary Fig. 1b)50,51. This evidence concerns the gene CCL5 and neoplasm.